Details

Autor(en) / Beteiligte

• Saez‐Giménez, Berta
• Berastegui, Cristina
• Barrecheguren, Miriam
• Revilla‐López, Eva
• Los Arcos, Ibai
• Alonso, Rodrigo
• Aguilar, Myriam
• Mora, Víctor M.
• Otero, Isabel
• Reig, Juan P.
• Quezada, Carlos A.
• Pérez, Virginia
• Valle, Manuel
• Laporta, Rosalía
• Deu, María
• Sacanell, Judith
• Bravo, Carles
• Gavalda, Joan
• Lopez‐Meseguer, Manuel
• Monforte, Víctor

Titel

COVID‐19 in lung transplant recipients: A multicenter study

Ist Teil von

• American journal of transplantation, 2021-05, Vol.21 (5), p.1816-1824

Ort / Verlag

United States: Elsevier Limited

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• This study describes the clinical presentation, treatment, and outcomes of SARS‐CoV‐2 infection in lung transplant recipients (LTRs). This is a multicenter, retrospective study of all adult LTRs with confirmed SARS‐CoV‐2 infection from March 4 until April 28, 2020 in six Spanish reference hospitals for lung transplantation. Clinical and radiological data, treatment characteristics, and outcomes were reviewed. Forty‐four cases were identified in that period. The median time from transplantation was 4.2 (interquartile range: 1.11–7.3) years. Chest radiography showed acute parenchymal abnormalities in 32 (73%) cases. Hydroxychloroquine was prescribed in 41 (93%), lopinavir/ritonavir (LPV/r) in 14 (32%), and tocilizumab in 19 (43%) patients. There was a strong interaction between tacrolimus and LPV/r in all cases. Thirty‐seven (84%) patients required some degree of respiratory support and/or oxygen therapy, and 13 (30%) were admitted to intermediate or intensive critical care units. Seventeen (39%) patients had died and 20 (45%) had been discharged at the time of the last follow‐up. Deceased patients had a worse respiratory status and chest X‐ray on admission and presented with higher D‐dimer, interleukin‐6, and lactate dehydrogenase levels. In this multicenter LTR cohort, SARS‐CoV‐2 presented with high mortality. Additionally, the severity of disease on presentation predicted subsequent mortality. A national cohort of lung transplant recipients with SARS‐CoV‐2 infection shows high severity and mortality.